Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

NCT06738966 is registered in ClinicalTrials.gov with Shanghai Best-Link Bioscience, LLC as lead sponsor.

NCT NCT06738966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06738966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
Lead sponsor
Shanghai Best-Link Bioscience, LLC
Phase
Phase 1
Overall status
Recruiting
Start date
March 10, 2025
Completion date
December 26, 2027
Enrollment
9 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, endometrial cancer, ovarian cancer